Neumora (NMRA) COO Aurora Daljit Singh Exercises Options and Sells Shares

What Happened

• Aurora Daljit Singh, Chief Operating and Development Officer of Neumora Therapeutics (NMRA), exercised a total of 176,060 option shares (at $0.72 per share, total exercise cost ~$126,764) on Aug 20–21, 2026 and sold those same shares in open‑market transactions for aggregate gross proceeds of ~$269,967.
• On Aug 20, 2026 she also was granted 200,000 derivative shares (reported as an award/grant). The sale activity appears to be same‑day sales of exercised options (i.e., the exercised shares were sold shortly after conversion).

Key Details

• Transaction dates: Aug 20–21, 2026. Sales executed in multiple trades; weighted‑average sale prices reported were $1.51, $1.59 and $1.60 (per footnotes, actual trade prices ranged by trade).
• Exercise price and cost: exercised 176,060 shares at $0.72 each (total paid ≈ $126,764).
• Proceeds from sales: gross proceeds ≈ $269,967 (weighted averages reported; see footnotes for price ranges).
• Grant: 200,000 shares granted on Aug 20, 2026 (derivative award; vesting schedule described in filing).
• Shares owned after transaction: the filing does not state total aggregated holdings after these transactions.
• Notable footnotes: multiple trades with price ranges (report lists weighted averages and offers to provide per‑trade detail on request); some shares held via Aurora Family Trust; several option grants have multi‑year vesting schedules (see footnotes F4–F6); one option referenced as fully vested (F5).
• Filing/timeliness: Form 4 filed Aug 21, 2026 for trades on Aug 20–21 — filing appears timely.

Context

• These transactions are typical option exercises followed by immediate open‑market sales (a cashless or sell‑to‑cover pattern). The filing also shows a separate 200,000‑share grant that vests over four years (25% after one year, then monthly thereafter). Derivative entries reported with $0.00 reflect conversion/cancellation of option interests upon exercise, per standard Form 4 reporting.
• The filing is factual and does not state motivations. Purchases/awards (the 200k grant) and exercises are different from outright open‑market purchases; sales of exercised shares realize proceeds rather than indicating an independent open‑market sell decision.